Liquid biopsy-based longitudinal monitoring of copy number variations in six biomarker genes reveals exploratory associations with disease progression and treatment resistance in localized soft tissue sarcomas

Introduction: Soft tissue sarcomas (STS) are rare cancers without validated biomarkers for monitoring or prognosis. Liquid biopsy (LB) enables minimally invasive tumor tracking. Objectives: This study aims to identify prognostic biomarkers in STS by assessing whether copy number variations (CNVs) of key genes correlate with outcomes, enabling early risk stratification and monitoring. Methods: We conducted a preliminary longitudinal CNV analysis in plasma cell-free DNA from 19 patients using droplet digital polymerase chain reaction, measuring CNVs at multiple treatment stages (B1–B6). Statistical analyses were performed in R (v.4.4.3). Continuous variables are shown as median (interquartile range), and categorical variables as counts (%). Benjamini–Hochberg adjustment was applied, and progression-free survival (PFS) was analyzed using Kaplan–Meier and the log-rank test. Results: Associations between CNVs and tumor size, necrosis, treatment response, disease progression, and PFS were observed. B1–B4 showed interconnected CNVs, involving TP53, RB1, MDM2, BRAF, MET, and HSP90. Progression may be associated with elevated CNVs for MDM2 and MET during chemotherapy (B2), and for TP53, RB1, MDM2, and HSP90 following radiotherapy (B3). At baseline, MDM2 CNV was higher in non-responders and increased during therapy in patients who subsequently experienced progression, which may be associated with poorer response to chemotherapy and radiotherapy. A p-value minimization framework suggested gene-specific CNV thresholds at B2 and B3, with higher CNV linked to shorter PFS. Conclusion: Longitudinal LB profiling indicates that genomic changes in STS are linked to outcomes and resistance. MDM2 emerged as a potential biomarker. Given the small, exploratory study cohort, these findings need cautious interpretation and validation in larger groups.

Authors

Institutions

Publication Details

Journal
Eurasian Journal of Medicine and Oncology
Published
2026-11-16
DOI
https://doi.org/10.36922/ejmo026260300
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Liquid biopsy-based longitudinal monitoring of copy number variations in six biomarker genes reveals exploratory associations with disease progression and treatment resistance in localized soft tissue sarcomas

Deepak Kala, Izabela Ziuzia-Graczyk, Anna Staniszewska, Łukasz Kuryk et al.
2 links
Eurasian Journal of Medicine and Oncology
Sarcoma Diagnosis and Treatment
article

Liquid biopsy-based longitudinal monitoring of copy number variations in six biomarker genes reveals exploratory associations with disease progression and treatment resistance in localized soft tissue sarcomas

Deepak Kala, Izabela Ziuzia-Graczyk, Anna Staniszewska, Łukasz Kuryk, Aneta Maria Borkowska, Monika Staniszewska, Teresa Szczepińska, Piotr Rutkowski, Wiktoria Trynkos, Michał Sitek, Ewelina Holm Bidstrup
article en

Abstract

Introduction: Soft tissue sarcomas (STS) are rare cancers without validated biomarkers for monitoring or prognosis. Liquid biopsy (LB) enables minimally invasive tumor tracking. Objectives: This study aims to identify prognostic biomarkers in STS by assessing whether copy number variations (CNVs) of key genes correlate with outcomes, enabling early risk stratification and monitoring. Methods: We conducted a preliminary longitudinal CNV analysis in plasma cell-free DNA from 19 patients using droplet digital polymerase chain reaction, measuring CNVs at multiple treatment stages (B1–B6). Statistical analyses were performed in R (v.4.4.3). Continuous variables are shown as median (interquartile range), and categorical variables as counts (%). Benjamini–Hochberg adjustment was applied, and progression-free survival (PFS) was analyzed using Kaplan–Meier and the log-rank test. Results: Associations between CNVs and tumor size, necrosis, treatment response, disease progression, and PFS were observed. B1–B4 showed interconnected CNVs, involving TP53, RB1, MDM2, BRAF, MET, and HSP90. Progression may be associated with elevated CNVs for MDM2 and MET during chemotherapy (B2), and for TP53, RB1, MDM2, and HSP90 following radiotherapy (B3). At baseline, MDM2 CNV was higher in non-responders and increased during therapy in patients who subsequently experienced progression, which may be associated with poorer response to chemotherapy and radiotherapy. A p-value minimization framework suggested gene-specific CNV thresholds at B2 and B3, with higher CNV linked to shorter PFS. Conclusion: Longitudinal LB profiling indicates that genomic changes in STS are linked to outcomes and resistance. MDM2 emerged as a potential biomarker. Given the small, exploratory study cohort, these findings need cautious interpretation and validation in larger groups.

Eurasian Journal of Medicine and OncologyVol. 0(0)
Warsaw University of Technology (PL), Medical University of Warsaw (PL), Institute of High Pressure Physics (PL), Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy (PL), Central Clinical Hospital (PL), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Polish Academy of Sciences (PL)
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon